banner
bioinformant.bsky.social
BioInformant - Stem Cell Industry News
@bioinformant.bsky.social
170 followers 620 following 130 posts
As the first and only market research firm to specialize in the stem cell industry, BioInformant.com is read by nearly 1 million readers per year. BioInformant has been cited by WSJ, Xconomy, and Vogue, as well as featured in Tony Robbin's book Life Force.
Posts Media Videos Starter Packs
bioinformant.bsky.social
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 14h
Kexing Biopharm’s Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Registered with FDA DMF - bioinformant.com/kexing-bioph...
Kexing Biopharm's Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes Registered with FDA DMF | BioInformant
SHENZHEN, China, Sept. 16, 2025 — Kexing Biopharm announced that its investigational Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes has successfully completed a Type II Drug Master File (...
bioinformant.com
bioinformant.bsky.social
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 1d
Maryland Governor Wes Moore to Speak at TEDCO’s 2025 Entrepreneur Expo - bioinformant.com/maryland-gov...

TEDCO, Maryland’s economic engine for technology companies, announces the attendance of Maryland Governor Wes Moore at the upcoming 2025 Entrepreneur Expo on Oct 21, 2025.
Maryland Governor Wes Moore to Speak at TEDCO's 2025 Entrepreneur Expo | BioInformant
Join us in College Park on October 21 during the lunch keynote session COLUMBIA, Md., Sept. 29, 2025 — TEDCO, Maryland’s economic engine for technology companies, announces the attendance of Maryland ...
bioinformant.com
bioinformant.bsky.social
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 1d
Qkine launches cell therapy grade recombinant proteins to support next-generation therapies - bioinformant.com/qkine/
@qkine.bsky.social
Qkine launches cell therapy grade recombinant proteins to support next-generation therapies | BioInformant
1st October 2025, Cambridge, UK – Qkine, Ltd., a specialist bioactive protein manufacturer with its core technology developed at the University of Cambridge, today announced the launch of its Cell The...
bioinformant.com
bioinformant.bsky.social
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 2d
Heartbeat.bio and Boehringer Ingelheim Use Human iPSC-Based Cardioids to Model Inherited Cardiomyopathies - bioinformant.com/heartbeat-bi...
HeartBeat.bio and Boehringer Ingelheim Use Human iPSC-Based Cardioids to Model Inherited Cardiomyopathies | BioInformant
HeartBeat.bio Joins Forces with Boehringer Ingelheim to Advance Gene Therapies for Inherited Heart Muscle Disorders Vienna, Austria – September 23, 2025 – HeartBeat.bio has entered into a research col...
bioinformant.com
bioinformant.bsky.social
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 2d
Clinical #StemCell Services: REPROCELL's experts in cell therapy manufacturing will take you through all the stages of your regenerative medicine project

www.reprocell.com/clinical-ste...
1
bioinformant.bsky.social
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 3d
CytoMed Expands NK cells from Stored Cord Blood, Creates to New Cord Blood-Derived Biotech Under LongevityBank - bioinformant.com/cytomed-ther...

@cytomedtech.bsky.social
CytoMed Expands NK cells from Stored Cord Blood, Creates to New Cord Blood-Derived Biotech Under LongevityBank | BioInformant
CytoMed Therapeutics Seeks to Advance Cord Blood-Derived Therapies For Auto-immune Diseases and Cancers Long-term intention is to spin off LongevityBank as standalone biotech, offering immune cell ban...
bioinformant.com
1
bioinformant.bsky.social
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 5d
Mytos Advances Automated iPSC Manufacturing through Strategic Partnerships with StemSight, Rinri Therapeutics, and Novadip - bioinformant.com/mytos-announ...
Mytos Advances Automated iPSC Manufacturing through Strategic Partnerships with StemSight, Rinri Therapeutics, and Novadip | BioInformant
Mytos Announces Strategic Partnerships with StemSight, Rinri Therapeutics, and Novadip to Power Next-Generation Cell Therapy Trials Mytos’ iDEM platform replaces traditional iPSC manufacturing with a ...
bioinformant.com
bioinformant.bsky.social
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 8d
European Commission Grants First Approval for Expanded Cord Blood Stem Cell Therapy (Zemcelpro®) - bioinformant.com/european-com...
European Commission Grants First Approval for Expanded Cord Blood Stem Cell Therapy (Zemcelpro®) | BioInformant
September 10, 2025 — In a landmark move for regenerative medicine, the European Commission has conditionally authorized Zemcelpro®, the first treatment in Europe to use expanded umbilical cord blood s...
bioinformant.com
bioinformant.bsky.social
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 12d
Takara Bio Europe launches Cellartis® MSC EV Wonder™, a defined, xeno-free medium for high-yield EV production - bioinformant.com/takara-bio-e...
Takara Bio Europe launches Cellartis® MSC EV Wonder™, a defined, xeno-free medium for high-yield EV production | BioInformant
September 24, 2025 – Takara Bio Europe announces the launch of Cellartis® MSC EV Wonder™, a defined, xeno-free medium engineered for the scalable production of extracellular vesicles (EVs) from human ...
bioinformant.com
bioinformant.bsky.social
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 12d
Ncardia Launches First-of-Its-Kind iPSC-Derived Non-Human Primate Cardiomyocytes to Advance Cardiac Safety Research - bioinformant.com/ncardia-ipsc...
Ncardia Launches First-of-Its-Kind iPSC-Derived Non-Human Primate Cardiomyocytes to Advance Cardiac Safety Research | BioInformant
LEIDEN, Netherlands — Ncardia, a leader in stem cell–based solutions for drug discovery and safety assessment, today announced the launch of Ncyte® NHP-C vCardiomyocytes, the first commercially availa...
bioinformant.com
bioinformant.bsky.social
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 13d
Congress Moves to Reauthorize Funding for National Cord Blood and Bone Marrow Transplant Programs - bioinformant.com/fundering-co...
Congress Moves to Reauthorize Funding for National Cord Blood and Bone Marrow Transplant Programs | BioInformant
Legislation would authorize $280 million over 5 years to support National Cord Blood and Bone Marrow Transplant Programs. A bipartisan group of lawmakers in the U.S. House has introduced new legislati...
bioinformant.com
bioinformant.bsky.social
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 14d
Precision Over Hype: Biogenomics’ Genovia Sets a New Standard in #Exosome-Based Regenerative Aesthetics - bioinformant.com/precision-ov...
Precision Over Hype: Biogenomics’ Genovia Sets a New Standard in Exosome-Based Regenerative Aesthetics | BioInformant
Los Angeles, CA – September 4, 2025 – As industry scrutiny intensifies over cosmetic products making bold but unverified “exosome” claims, Biogenomics, a biotech company advancing regenerative aesthet...
bioinformant.com
bioinformant.bsky.social
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 14d
Sanatela AT Medical Solutions Inc. Announces Groundbreaking Patent Issuance for Cancer Stem Cell Identification and Precision Treatment Platform - bioinformant.com/sanatela-at-...
Sanatela AT Medical Solutions Inc. Announces Groundbreaking Patent Issuance for Cancer Stem Cell Identification and Precision Treatment Platform | BioInformant
Rochester, NY, September 24, 2025 – After two decades of pioneering hematology and cancer stem cell research, Sanatela AT Medical Solutions Inc. proudly announces that the United States Patent and Tra...
bioinformant.com
bioinformant.bsky.social
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 18d
Shineco Establishes Biological Cell Digital Division to Integrate iPSC Technology Assets with Blockchain Technology - bioinformant.com/shineco-biol...
Shineco Establishes Biological Cell Digital Division to Integrate iPSC Technology Assets with Blockchain Technology | BioInformant
BEIJING, Aug. 13, 2025 — Shineco Inc. (NASDAQ: SISI), a manufacturer of induced pluripotent stem cell (iPSC) technology platforms, announced the establishment of a Biological Cell Digital Business Div...
bioinformant.com
bioinformant.bsky.social
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 19d
AABB’s Cell and Gene Therapy Standards for Pharmacy, First Edition, Takes Effect October 1 - bioinformant.com/aabbs-cell-a...
@aabbupdates.bsky.social
AABB’s Cell and Gene Therapy Standards for Pharmacy, First Edition, Takes Effect October 1 | BioInformant
Sept 8, 2025, Bethesda, MD – The Association for the Advancement of Blood & Biotherapies (AABB) is pleased to announce the release of the first edition of Cell and Gene Therapy Standards for Pharmacy,...
bioinformant.com
1 1
bioinformant.bsky.social
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 23d
Cord Blood Industry Consolidation Escalates in 2025 - bioinformant.com/cord-blood-i...
Cord Blood Industry Consolidation Escalates in 2025 | BioInformant
The cord blood industry had strong growth during the early 2000's. However, the market has matured and consolidated over the past 10 years.
bioinformant.com
bioinformant.bsky.social
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 24d
EU Grants Approval to Zemcelpro, a Cord Blood–Derived Stem Cell Therapy for Blood Cancer Patients - bioinformant.com/eu-grants-ap...
EU Grants Approval to Zemcelpro, a Cord Blood–Derived Stem Cell Therapy for Blood Cancer Patients | BioInformant
In August 2025, the European Commission (EC) granted conditional marketing authorization (CMA) to Cordex Biologics, a subsidiary of ExCellThera, for Zemcelpro® (UM171 Cell Therapy), a personalized ste...
bioinformant.com
bioinformant.bsky.social
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 26d
Cartherics Wins ‘Most Promising iPSC Therapy Pipeline in APAC’ at Asia Pacific Cell & Gene Therapy Excellence Awards - bioinformant.com/cartherics-m...
Cartherics Wins ‘Most Promising iPSC Therapy Pipeline in APAC’ at Asia Pacific Cell & Gene Therapy Excellence Awards | BioInformant
Melbourne, Australia, 11 September 2025 –  Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing off-the-shelf immune cell therapies focusing on high-impact women’s diseas...
bioinformant.com
1 1
bioinformant.bsky.social
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 26d
I'm excited to announce the 5th iPSC Drug Development Summit (Oct 1–2, 2025, Boston), the industry’s leading forum advancing iPSC-derived therapies hosted by Hanson Wade.

ipsc-therapies-summit.com/about/about-...

#ipscells #drugdiscovery #drugdevelopment
About Event | iPSC Drug Development Summit
The 5th iPSC Drug Development Summit is the longest-standing and most comprehensive meeting focused exclusively on iPSC-derived therapies
ipsc-therapies-summit.com
1
bioinformant.bsky.social
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 27d
Mirugen Secures A$4.5M to Advance In Vivo Cell (Re)programming, Positioning Itself as a Pioneer in the Field - bioinformant.com/mirugen-secu...
Mirugen Secures A$4.5M to Advance In Vivo Cell (Re)programming, Positioning Itself as a Pioneer in the Field | BioInformant
Mirugen has built a strong syndicate of Australia’s leading life science and deep tech investors to drive its next phase of growth, appointing seasoned biotech entrepreneur Charlotte Casebourne Stock ...
bioinformant.com
2
bioinformant.bsky.social
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · 29d
Regenerelle® Issues Response to FDA Untitled Letter - bioinformant.com/regenerelle-...

Regenerelle®, a leader in Wharton’s Jelly Mesenchymal Stromal Cells (WJ-MSCs) & exosomes derived from WJ-MSCs, announced the public release of its full response to the U.S. FDA Untitled Letter dated May 22, 2023.
bioinformant.bsky.social
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · Sep 7
Gameto Secures $44M Series C to Advance Fertilo as First iPSC-Derived Reproductive Therapy to Reach Phase 3 in the U.S. - bioinformant.com/gametos-ipsc...
Gameto Secures $44M Series C to Advance Fertilo as First iPSC-Derived Reproductive Therapy to Reach Phase 3 in the U.S. | BioInformant
As birth rates decline and US IVF access falls further behind, Gameto recruits first Phase 3 patients for cutting-edge biotechnology to reignite reproductive health possibilities Company’s $127 millio...
bioinformant.com
1
bioinformant.bsky.social
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · Aug 26
The Scalable Solution for 10X Exosome Yield: AgentV-DSP

AgentV™-DSP, a solution from RoosterBio, is designed to prevent filter fouling and deliver novel processing advantages, including greater filter loading capacity and higher #exosome yield.

www.roosterbio.com/products/age...
1 1
bioinformant.bsky.social
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · Aug 22
Novel iPSC-Based Vaccine Shows Promise Against Colorectal Cancer - bioinformant.com/novel-ipsc-b...
Novel iPSC-Based Vaccine Shows Promise Against Colorectal Cancer | BioInformant
Colorectal cancer (CRC) remains one of the leading causes of cancer-related deaths worldwide, claiming nearly a million lives each year. Despite advances in screening, surgery, and chemotherapy, the d...
bioinformant.com
2
bioinformant.bsky.social
BioInformant - Stem Cell Industry News @bioinformant.bsky.social · Aug 17
Japan Moves Toward Permitting Fertilized Embryo Research Using iPSC-Derived Eggs and Sperm - bioinformant.com/japan-fertil...
Japan Moves Toward Permitting Fertilized Embryo Research Using iPSC-Derived Eggs and Sperm | BioInformant
A Japanese government bioethics panel has given the green light to a controversial but closely regulated area of research: the creation of human embryos using lab-generated sperm and eggs derived from...
bioinformant.com
1